Metoprolol
Based on 15 publication(s) in Google Scholar
Metoprolol is an orally active, selective β1-adrenoceptor antagonist. Metoprolol shows anti-inflammation, antitumor and anti-angiogenic properties.
For research use only. We do not sell to patients.
- Purity: 99.99%
- CAS No.: 51384-51-1
- Formula: C15H25NO3
- Molecular Weight:267.36
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Apoptosis Compound Library
HY-L003
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Anti-Aging Natural Product Library
HY-L134
-
Off-patent Drug Library
HY-L141
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
-
Classic FDA-Approved Drug Library
HY-L261
Publications Citing Use of MedChemExpress (MCE) Metoprolol
More- J Intern Med. 2024 Sep;296(3):291-297. [Abstract]
- Chemosphere. 2019 Jun:225:378-387. [Abstract]
- Emerg Contam. 2026 Feb 23.
- Eur J Med Chem. 2024 Dec 5:279:116842. [Abstract]
- Int Immunopharmacol. 2024 Aug 9:140:112894. [Abstract]
- iScience. 2025 Jan 17;28(2):111831. [Abstract]
- Environ Toxicol. 2024 Mar;39(3):1682-1699. [Abstract]
- J Pharm Biomed Anal. 2021 Feb 20:195:113870. [Abstract]
- J Pharmacol Sci. 2020 Sep;144(1):30-42. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jul 1:1227:123804. [Abstract]
- PLoS One. 2024 Aug 14;19(8):e0301875. [Abstract]
- Biochem Biophys Res Commun. 2025 Oct 30:786:152756. [Abstract]
- SSRN. 2024 May 30.
- bioRxiv. 2024 Mar 29.
- Preprints. 2023 Jun 19.
Customer Validation & Images
-
Others
-
Bio/Physico-chemical Assay
-
IF
All Adrenergic Receptor Isoforms
More
Biological Activity
|
β1 adrenoceptor |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A-375 | IC50 |
>100 μM
Compound: Metoprolol
|
Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human A375 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 32216987] |
| HEK293 | IC50 |
>1000 μM
Compound: 95
|
Inhibition of RyR2 R4496C mutant (unknown origin)-mediated store-overload induced calcium release expressed in HEK293 cells after 8 to 10 mins by fura-2/AM dye-based fluorescence assay
Inhibition of RyR2 R4496C mutant (unknown origin)-mediated store-overload induced calcium release expressed in HEK293 cells after 8 to 10 mins by fura-2/AM dye-based fluorescence assay
|
[PMID: 24124794] |
| SK-MEL-28 | IC50 |
>100 μM
Compound: Metoprolol
|
Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human SK-MEL-28 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 32216987] |
| SK-MEL-5 | IC50 |
>100 μM
Compound: Metoprolol
|
Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
Antiproliferative activity against human SK-MEL-5 cells assessed as cell growth inhibition incubated for 48 hrs by MTT assay
|
[PMID: 32216987] |
Metoprolol (0-1000 μg/mL; 24-72 h) shows cytotoxic effect on U937 and MOLT-4 cells dose and time dependently[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U937 and MOLT-4 cells
-
Concentration:1, 10, 50, 100, 500 and 1000 μg/mL
-
Incubation Time:24, 48 and 72 h
-
Result:Significantly decreased the viability of U937 and MOLT-4 cells at 1000 μg/mL (3740.14µM) concentration after 48 hours incubation time, significantly reduced the viability of U937 cells at ≥500 μg/ml (≥1870.07µM) concentrations after 72 hours incubation time, and significantly decreased the viability of MOLT4 cells at ≥100 μg/ml (≥374.01µM) concentrations after 72 hours incubation.
Metoprolol (15 mg/kg/q12h; i.g.; 5 days) shows anti-inflammation and anti-virus effects in murine model with coxsackievirus B3-induced viral myocarditis[2].
Metoprolol (2.5 mg/kg; i.v.; 3 bolus injections) significantly decreased activated caspase-9 protein expression and inhibits myocardial apoptosis in coronary microembolization (CME) rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male ApoE−/− mice[1]
-
Dosage:2.5 mg/kg/h
-
Administration:Via osmotic minipumps, 11 weeks
-
Result:Significantly reduced atherosclerotic plaque area in thoracic aorta, reduced serum TNFα and the chemokine CXCL1 as well as decreasing the macrophage content in the plaques.
-
Animal Model:Balb/c mice, coxsackievirus B3 (CVB3) induced viral myocarditis (VMC) model[2]
-
Dosage:15 mg/kg/q12h
-
Administration:Oral gavage, 5 consecutive days
-
Result:Reduced pathological scores of VMC induced by CVB3 infection, protected the myocardium against viral damage by reducing serum cTn-I levels. Decreased the levels of myocardial pro-inflammatory cytokines and increase the expression of anti-inflammatory cytokine. Significantly decreased myocardial virus titers.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 51384-51-1
-
Appearance Solid
-
Molecular Weight 267.36
-
Formula C15H25NO3
-
Color White to off-white
-
SMILES
OC(CNC(C)C)COC1=CC=C(CCOC)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
J Intern Med
SARS-CoV-2 spike protein acts as a β-adrenergic receptor agonist: A potential mechanism for cardiac sequelae of long COVID. [Abstract]2024 Sep;296(3):291-297. PMID: 39073192
Metoprolol purchased from MedChemExpress. Usage Cited in: J Intern Med. 2024 Sep;296(3):291-297. [Abstract]
Selective blockers Metoprolol (METO; β1-AR blocker; 10 µmol/L) and ICI118551 (ICI; β2-AR blocker; 10 µmol/L) were used to explore the interactions of the spike protein with β1-AR and β2-AR, respectively.
Metoprolol purchased from MedChemExpress. Usage Cited in: J Intern Med. 2024 Sep;296(3):291-297. [Abstract]
cAMP accumulation in NMCMs treated with ISO (1 µmol/L) and the spike trimer (10 nmol/L) with or without pretreatment with Metoprolol (10 µmol/L) and ICI118551 (10 µmol/L).
-
Chemosphere
Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. [Abstract]2019 Jun:225:378-387. PMID: 30884299 -
-
Eur J Med Chem
2024 Dec 5:279:116842. PMID: 39260319 -
Int Immunopharmacol
Baricitinib alleviates cardiac fibrosis and inflammation induced by chronic sympathetic activation. [Abstract]2024 Aug 9:140:112894. PMID: 39126736 -
iScience
Stimulation of TRPV1+ peripheral somatosensory nerves suppress inflammation via the somato-autonomic reflex. [Abstract]2025 Jan 17;28(2):111831. PMID: 39967868 -
Environ Toxicol
Phenylacetyl glutamine (PAGln) enhances cardiomyocyte death after myocardial infarction through β1 adrenergic receptor. [Abstract]2024 Mar;39(3):1682-1699. PMID: 38041472 -
J Pharm Biomed Anal
Screening method of mildronate and over 300 doping agents by reversed-phase liquid chromatography-high resolution mass spectrometry. [Abstract]2021 Feb 20:195:113870. PMID: 33453569 -
J Pharmacol Sci
Sustained increased CaMKII phosphorylation is involved in the impaired regression of isoproterenol-induced cardiac hypertrophy in rats. [Abstract]2020 Sep;144(1):30-42. PMID: 32665128 -
J Chromatogr B Analyt Technol Biomed Life Sci
High-throughput screening of LogD by using a sample pooling approach based on the traditional shake flask method. [Abstract]2023 Jul 1:1227:123804. PMID: 37393793 -
PLoS One
Ginseng Radix et Rhizoma enhanced the effect of metoprolol in chronic heart failure by inhibiting autophagy in male C57BL/6J mice. [Abstract]2024 Aug 14;19(8):e0301875. PMID: 39141645 -
Biochem Biophys Res Commun
Dual-cardiotoxicity evaluation of torsadogenic risk drugs using human iPSC-derived cardiomyocytes. [Abstract]2025 Oct 30:786:152756. PMID: 41043280 -
Metoprolol purchased from MedChemExpress. Usage Cited in: SSRN. 2024 May 30.
Quantification of immunofluorescence staining of phosphorylated-GSK3β in NRCFs. The ratio of phosphorylated protein to total protein reflects the activation of signaling pathways. NRCFs were starved for 24h. Mig and Metoprolol (Met: 10 μM) were added ahead for 1h, then ISO was added for 24h. Met was used as positive control.
-
-
Solvent & Solubility
DMSO : 100 mg/mL (374.03 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.35 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ulleryd MA, et al. Metoprolol reduces proinflammatory cytokines and atherosclerosis in ApoE-/- mice. Biomed Res Int. 2014;2014:548783. [Content Brief]
[2]. Wang D, et al. Carvedilol has stronger anti-inflammation and anti-virus effects than metoprolol in murine model with coxsackievirus B3-induced viral myocarditis. Gene. 2014 Sep 1;547(2):195-201. [Content Brief]
[4]. Su Q, et al. Effect of metoprolol on myocardial apoptosis and caspase-9 activation after coronary microembolization in rats. Exp Clin Cardiol. 2013 Spring;18(2):161-5. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7403 mL | 18.7014 mL | 37.4028 mL | 93.5069 mL |
| 5 mM | 0.7481 mL | 3.7403 mL | 7.4806 mL | 18.7014 mL | |
| 10 mM | 0.3740 mL | 1.8701 mL | 3.7403 mL | 9.3507 mL | |
| 15 mM | 0.2494 mL | 1.2468 mL | 2.4935 mL | 6.2338 mL | |
| 20 mM | 0.1870 mL | 0.9351 mL | 1.8701 mL | 4.6753 mL | |
| 25 mM | 0.1496 mL | 0.7481 mL | 1.4961 mL | 3.7403 mL | |
| 30 mM | 0.1247 mL | 0.6234 mL | 1.2468 mL | 3.1169 mL | |
| 40 mM | 0.0935 mL | 0.4675 mL | 0.9351 mL | 2.3377 mL | |
| 50 mM | 0.0748 mL | 0.3740 mL | 0.7481 mL | 1.8701 mL | |
| 60 mM | 0.0623 mL | 0.3117 mL | 0.6234 mL | 1.5584 mL | |
| 80 mM | 0.0468 mL | 0.2338 mL | 0.4675 mL | 1.1688 mL | |
| 100 mM | 0.0374 mL | 0.1870 mL | 0.3740 mL | 0.9351 mL |
Powered by Bioz